Pear Therapeutics Pronounces Publication of New Evaluation of Actual-World Knowledge Displaying Discount in Insomnia Severity, Healthcare Useful resource Utilization and Related Prices in Adults Utilizing Somryst®

BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR), the chief in growing and commercializing software-based medicines known as prescription digital therapeutics (PDTs), as we speak introduced the publication of recent outcomes from a well being financial evaluation of real-world information to guage healthcare useful resource utilization, related prices and insomnia severity for Somryst^® (beforehand referred to as SHUTi in its prior incarnation), the one FDA-authorized PDT for the therapy of continual insomnia.

Outcomes confirmed clinically significant reductions in health-related companies and prices within the 24-months after Somryst initiation in comparison with 24-months prior. Additional, clinically significant reductions in ISI have been additionally discovered at end-of-treatment at 9 weeks in comparison with baseline. The retrospective evaluation was printed within the worldwide peer-reviewed journal ClinicoEconomics and Outcomes Analysis.¹

“These real-world information underscore the potential scientific utility and sturdy financial good thing about a prescription digital therapeutic like Somryst amongst folks with continual insomnia,” mentioned Yuri Maricich, M.D., Chief Medical Officer of Pear Therapeutics. “Within the final 24 months, lack of sleep has been exacerbated by the continuing COVID-19 pandemic and may significantly influence not solely day-to-day actions, but additionally general high quality of life and long-term well being. Now, it’s particularly vital to look at digitally delivered therapy choices that may tackle the underlying problems with continual insomnia.”

The evaluation evaluated real-world information of 248 grownup sufferers with continual insomnia handled with Somryst over 24-months in comparison with the 24-months months previous to therapy and located:

• Reductions in health-related companies together with:
  • Emergency division visits (53%; IRR: 0.47; 95% CI 0.27, 0.82; P=0.008).
  • Hospitalizations (21%; IRR: 0.79; 95% CI 0.46, 1.352; P=0.3887).
  • Hospital outpatient visits (13%; IRR: 0.87; 95% CI 0.66, 1.14; P=0.315).
  • Variety of sufferers handled with sleep help medicines (18.5%)
• An estimated $2,059 discount in per-patient prices.¹

Additional, by finish of therapy at 9 weeks in comparison with baseline at therapy initiation, outcomes discovered:

• A 37.2% discount in imply insomnia severity index (ISI) rating (19.1 at baseline and 12.0 at 9 weeks).
• 58.9% of handled individuals achieved ISI responder standing (ISI rating improved by >7).
• 26.6% of handled individuals achieved insomnia remission (ISI rating <8) (0 at baseline and 66 at 9 weeks).¹

The total paper is accessible on-line by clicking right here.

About Somryst^®

Somryst is the one FDA-authorized therapeutic that delivers guideline beneficial first-line therapy for continual insomnia. Somryst is a 9-week prescription digital therapeutic (PDT) that addresses the underlying problems with continual insomnia by delivering cognitive behavioral remedy for insomnia (CBTi), an evidence-based method that trains the mind to sleep. The American Academy of Sleep Medication and the American School of Physicians scientific tips advocate CBTi as first-line therapy for folks with continual insomnia.^2,3 Somryst is used on a cell gadget, comparable to a smartphone or pill and is accessible by prescription solely. A licensed Well being Care Supplier (HCP) should prescribe Somryst and use of Somryst ought to be undertaken solely below the supervised care of an HCP.

Somryst Indications for Use and Essential Security Info

Somryst is a prescription-only digital therapeutic meant to offer a neurobehavioral intervention (Cognitive Behavioral Remedy for Insomnia – CBT-I) to sufferers 22 years of age and older with continual insomnia. Somryst treats sufferers with continual insomnia by enhancing a affected person’s insomnia signs.

Security Info and Warnings

Somryst will not be for everybody. Please use your scientific judgment to find out whether or not Somryst is true on your affected person.

• Somryst will not be for emergency use. Please instruct sufferers to dial 911 or to go to the closest emergency room within the occasion of a medical emergency.
• Sufferers ought to be clearly instructed to not use Somryst to speak extreme, important, or pressing data to their Well being Care Supplier.
• Somryst will not be meant for use as therapy with out supervision of a Well being Care Supplier.
• Somryst will not be meant to be a substitution for any therapy treatment.
• Somryst accommodates delicate medical data. Please instruct sufferers to guard their data by password-protecting their smartphone and pill, making certain nobody else might entry their gadget.
• Sleep Restriction (and Consolidation) inside Somryst could cause sleepiness, particularly within the early levels of utilizing the PDT. Somryst shouldn’t be used if the affected person must be alert or cautious to keep away from critical accidents of their job or day by day life. Examples embrace:
  • Lengthy-haul truck drivers
  • Lengthy-distance bus drivers
  • Air visitors controllers
  • Operators of heavy equipment
  • Some meeting line jobs
  • The utilization information collected in remedy classes by Somryst aren’t meant for use as a standalone evaluation of therapy progress.

Observe: Within the early levels of therapy, elevated daytime sleepiness could also be anticipated, however it’s often non permanent. Please instruct the affected person to seek the advice of with their Well being Care Supplier if these experiences don’t go away over just a few weeks, as it could point out that they’ve one other sleep problem or medical situation apart from insomnia. Please instruct the affected person that if they’ve hassle staying awake whereas performing probably harmful duties (like driving) at any level within the therapy, to keep away from these harmful duties or cease following the sleep restriction element of the remedy. This press launch doesn’t embrace all the data wanted to make use of Somryst safely and successfully. Please see the total Clinician Temporary Abstract Directions for Somryst for extra data.

About Pear Therapeutics

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the father or mother firm of Pear Therapeutics (US), Inc. Pear is the chief in growing and commercializing software-based medicines, known as prescription digital therapeutics (PDTs). Pear goals to redefine care by the widespread use of clinically validated software-based therapeutics to offer higher outcomes for sufferers, smarter engagement and monitoring instruments for clinicians, and cost-effective options for payers. Pear has the primary end-to-end platform to find, develop, and ship PDTs to sufferers and a pipeline of merchandise and product candidates throughout therapeutic areas, together with the primary three PDTs with illness therapy claims from the FDA. Pear’s product, reSET^®, for the therapy of substance use dysfunction, was the primary PDT to obtain advertising and marketing authorization from the FDA to deal with illness. Pear’s second product, reSET-O^®, for the therapy of opioid use dysfunction, was the primary PDT to obtain Breakthrough Designation. Pear’s third product, Somryst^® for the therapy of continual insomnia, was the primary PDT submitted by FDA’s conventional 510(okay) pathway whereas concurrently reviewed by FDA’s Software program Precertification Pilot Program. For extra data, go to Pear at www.peartherapeutics.com.

Ahead-Trying Statements

This press launch accommodates forward-looking statements inside the that means of the federal securities legal guidelines which might be topic to dangers and uncertainties and different elements which may trigger precise outcomes to vary materially from these expressed or implied by such forward-looking statements. Ahead-looking statements typically relate to future occasions involving, or future efficiency of, Pear. For instance, statements that point out scientific utility and sturdy financial good thing about sufferers utilizing Somryst will enhance are forward-looking statements. In some instances, you’ll be able to establish forward-looking statements by terminology comparable to “might”, “can” or variations of them or comparable terminology.

These forward-looking statements are primarily based upon estimates and assumptions that, whereas thought of cheap by Pear and its administration are inherently unsure. Elements which will trigger precise outcomes to vary materially from present expectations embrace, however aren’t restricted to: (i) delay or reluctance by sufferers and/or suppliers to undertake, request or use Pear’s merchandise, (ii) the chance that Pear could also be adversely affected by different financial, enterprise, regulatory, and/or aggressive elements; (iii) the evolution of the markets wherein Pear competes; (iv) the influence of the COVID-19 pandemic on Pear’s enterprise; (v) adjustments in relevant legal guidelines or rules; and (vi) different dangers and uncertainties set forth in Pear’s filings with the SEC (together with these described within the Danger Elements part). These filings will establish and tackle different vital dangers and uncertainties that might trigger precise occasions and outcomes to vary materially from these contained within the forward-looking statements.

Readers are cautioned to not put undue reliance on forward-looking statements, and Pear assumes no obligation and doesn’t intend to replace or revise these forward-looking statements, whether or not because of new data, future occasions, or in any other case.

References:

1. Forma F, Knight TG, Thorndike FP, Xiong X, Baik R, Velez FF, Maricich YA, Malone DC. Actual-World Analysis of Medical Response and Lengthy-Time period Healthcare Useful resource Utilization Patterns Following Remedy with a Digital Therapeutic for Persistent Insomnia. Clinicoecon Outcomes Res. 2022;14:537-546 https://doi.org/10.2147/CEOR.S368780
2. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Medical guideline for the analysis and administration of continual insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504.
3. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Administration of Persistent Insomnia Dysfunction in Adults: A Medical Follow Guideline From the American School of Physicians. Ann Intern Med. 2016; 165:125–133.